Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Mereo BioPharma Group plc before investing.

In this article, we go over a few key elements for understanding Mereo BioPharma Group plc’s stock price such as:

• Mereo BioPharma Group plc’s current stock price and volume
• Why Mereo BioPharma Group plc’s stock price changed recently
• Upgrades and downgrades for MREO from analysts
• MREO’s stock price momentum as measured by its relative strength

About Mereo BioPharma Group plc (MREO)

Before we jump into Mereo BioPharma Group plc’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of rare diseases in the United Kingdom and the United States. The company develops Setrusumab, an antibody for the treatment of osteogenesis imperfecta; Alvelestat, an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency associated lung disease; and Vantictumab, an anti-FZD monoclonal antibody for the treatment of autosomal dominant osteopetrosis type 2. It also develops Leflutrozole, an oral aromatase inhibitor, which is in Phase 2 trials for use in the treatment of hypogonadotropic hypogonadism; Navicixizumab, which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Etigilimab, an IgG1 monoclonal antibody which binds to the human TIGIT receptor on immune cells for the Treatment of advanced solid tumors; and Acumapimod, a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; and licensing agreement with AstraZeneca. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, United Kingdom.

Want to learn more about Mereo BioPharma Group plc’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Mereo BioPharma Group plc.

Mereo BioPharma Group plc’s Stock Price as of Market Close

As of September 04, 2026, 4:00 PM, CST, Mereo BioPharma Group plc’s stock price was $0.250.

Mereo BioPharma Group plc is down 8.16% from its previous closing price of $0.272.

During the last market session, Mereo BioPharma Group plc’s stock traded between $0.248 and $0.270. Currently, there are approximately 160.71 million shares outstanding for Mereo BioPharma Group plc.

Mereo BioPharma Group plc’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Mereo BioPharma Group plc Stock Price History

Mereo BioPharma Group plc’s (MREO) price is currently down 6.3% so far this month.

During the month of September, Mereo BioPharma Group plc’s stock price has reached a high of $0.290 and a low of $0.248.

Over the last year, Mereo BioPharma Group plc has hit prices as high as $2.370 and as low as $0.200. Year to date, Mereo BioPharma Group plc’s stock is down 40%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Mereo BioPharma Group plc Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of September 04, 2026, there was 1 analyst who downgraded Mereo BioPharma Group plc’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate Mereo BioPharma Group plc’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Mereo BioPharma Group plc’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Mereo BioPharma Group plc (MREO) by visiting AAII Stock Evaluator.

Relative Price Strength of Mereo BioPharma Group plc

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of September 04, 2026, Mereo BioPharma Group plc has a weighted four-quarter relative price strength of -28.60%, which translates to a Momentum Score of 7 and is considered to be Very Weak.

Want to learn more about how Mereo BioPharma Group plc is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Mereo BioPharma Group plc Stock Price: Bottom Line

As of September 4, 2026, Mereo BioPharma Group plc’s stock price is $0.250, which is down 8.16% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Mereo BioPharma Group plc stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.